INCB39110 is a potent JAK1 tyrosine kinase inhibitor, which is currently in Phase II trials for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis.
More Information Supplier PageINCB39110 is a potent JAK1 tyrosine kinase inhibitor, which is currently in Phase II trials for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis.
More Information Supplier PageINCB39110 is a potent JAK1 tyrosine kinase inhibitor, which is currently in Phase II trials for the treatment of rheumatoid arthritis, myelofibrosis, rheumatoid arthritis and plaque psoriasis.
More Information Supplier PageAfegostat was an experimental drug for the treatment of certain forms of Gaucher’s disease. The substance was used in form of the tartrate. Isofagomine (IFG) is an acid ??-glucosidase (GCase) active site inhibitor that acts as a pharmacological chaperone.
More Information Supplier PageAfegostat was an experimental drug for the treatment of certain forms of Gaucher’s disease. The substance was used in form of the tartrate. Isofagomine (IFG) is an acid ??-glucosidase (GCase) active site inhibitor that acts as a pharmacological chaperone.
More Information Supplier PageAfegostat was an experimental drug for the treatment of certain forms of Gaucher’s disease. The substance was used in form of the tartrate. Isofagomine (IFG) is an acid ??-glucosidase (GCase) active site inhibitor that acts as a pharmacological chaperone.
More Information Supplier PageAB05831 is a highly potent and specific inhibitor of beta-hexosaminidase.
More Information Supplier PageAB05831 is a highly potent and specific inhibitor of beta-hexosaminidase.
More Information Supplier PageDeoxynojirimycin is a Maltase-glucoamylase (a-glucosidase I and II) inhibitor. It interferes with N-linked glycosylation.
More Information Supplier PageBenzamide is the amide derivative of benzoic acid and an inhibitor of poly(ADP-ribose) polymerase-1 (PARP-1).
More Information Supplier Page
